High Tide Acquires 100% Equity of Northern Helm for $7.74M
High Tide announced that it will acquire 100% of the equity interest of J. Supply Holdings, operating as Northern Helm, resulting in High Tide's acquisition of four of the six retail cannabis stores currently operated by Northern Helm in Ontario for $7.74M. These acquisitions will bring High Tide's total store count to 228 Canna Cabana locations across Canada and 103 in the province of Ontario. The transaction, which is an arm's length transaction, is subject to, among other things, receipt of the required approvals from the TSX Venture Exchange and the Alcohol and Gaming Commission of Ontario, and the satisfaction of other customary conditions of closing, and is expected to close in the coming weeks. The consideration for the 100% of equity interests acquired will be approximately $3.2M in assumed debt with a 2% interest rate, with 40% of the remaining amount paid in cash, and the remaining 60% paid in common shares of High Tide on closing on the basis of a deemed price per High Tide Share equal to the 10-day volume weighted average price of the High Tide Shares on the TSXV ending on the trading day that is three business days prior to the closing date, subject to a floor price equal to the discounted market price as of the day prior to this news release. The High Tide Shares will be subject to a statutory and contractual hold period of four months and one day from the date of closing. The purchase price represents 4.5x the annualized adjusted EBITDA of the stores for the three months ended March 31.
Trade with 70% Backtested Accuracy
Analyst Views on HITI
About HITI
About the author

- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect directly with pharmacies and healthcare professionals in Germany, addressing patient demand for high-quality products.
- Positive Industry Response: The event garnered positive feedback from patients and healthcare professionals, indicating a rising demand for high-quality, trusted cannabis products, which enhances Remexian's competitive edge in the market.
- Strategic Investment: By continuously broadening its product offerings and strengthening supply chain relationships, Remexian aims to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing High Tide's strategy of leveraging its Canadian strengths for global diversification.
- Market Expansion: High Tide's subsidiary Remexian showcased exclusive medical cannabis distribution partnerships with several Canadian brands at the 2026 Mary Jane Berlin trade show, further solidifying its leading position in Germany's rapidly growing medical cannabis market.
- Diverse Product Portfolio: Remexian highlighted medical cannabis products from brands like Tribal and Highly Dutch Organic, emphasizing its expanding portfolio of exclusive distribution agreements that connect Canadian brands directly with pharmacies and healthcare professionals in Germany.
- Industry Opportunities: Germany is viewed as a significant growth opportunity in the global medical cannabis industry, and Remexian's participation not only enhances its reputation as a trusted importer of premium products but also fosters relationships with healthcare professionals, facilitating the expansion of its pharmacy network.
- Competitive Advantage: High Tide's CEO Raj Grover stated that by continuously broadening its product offerings and strengthening supply chain relationships, Remexian is positioning itself to capture a larger share of one of the world's most attractive medical cannabis markets, showcasing its unique procurement capabilities and market strategy.
- Significant Revenue Growth: High Tide Inc reported a record revenue of $179.3 million in Q2, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and indicating strong market performance and expansion potential.
- Record Gross Margin: The company achieved a gross profit of $48.4 million with a gross margin of 27%, the highest in eight quarters, showcasing improved profitability in its medical cannabis distribution segment, particularly in the German market.
- Strong Membership Growth: Cabana Club membership reached 2.65 million, up 39% year-over-year, with elite memberships soaring by 84%, which not only enhances customer loyalty but also lays a solid foundation for future sales growth.
- Enhanced Financial Flexibility: High Tide secured a $40 million credit facility with Bank of Montreal, boosting its financial flexibility; despite free cash flow being $1.5 million, the company is actively investing to support future expansion plans.
- Record Revenue: High Tide reported a record revenue of C$179.3 million for Q2 FY2026, reflecting a 30% year-over-year increase and surpassing estimates of C$171.15 million, indicating strong performance in the retail sector.
- Stable Market Share: Canna Cabana maintained a 12% market share, and excluding British Columbia's restrictions, its share increased to 14%, up from 13% last year, demonstrating robust growth in a competitive market.
- Improved Profitability: Adjusted EBITDA reached a record C$13.9 million, a 73% year-over-year increase and the fastest growth in nine quarters, despite having three fewer days in the quarter, showcasing effective cost control and operational efficiency.
- Medical Cannabis Distribution Growth: Remexian achieved a record distribution of 7.6 tonnes of medical cannabis in Germany, marking a 49% year-over-year and 21% sequential increase, further solidifying High Tide's position in the international market.
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
- Record Revenue: High Tide achieved a record revenue of CAD 179.3 million in Q2 2026, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and demonstrating strong performance in both Canadian and German markets.
- Medical Cannabis Growth: Remexian Pharma GmbH generated record revenue of CAD 31.6 million from medical cannabis sales in Germany, with gross margins increasing to 27%, indicating that the company's market share has now exceeded 14%, laying a solid foundation for future expansion.
- Positive Free Cash Flow: Although free cash flow was CAD 1.5 million, down from CAD 4.9 million last year, the company reported strong operating cash flow of CAD 8.8 million, showcasing its ongoing financial health and growth potential.
- Significant Membership Growth: Cabana Club membership has surpassed 2.65 million, up 39% year-over-year, while ELITE membership reached 178,000, an 84% increase, indicating continued improvement in customer loyalty and market share.








